HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) announced that new and updated clinical data will be presented at the ESMO Asia Congress (Dec 5‑7, 2025, Singapore) and the ASH Annual Meeting (Dec 6‑9, 2025, Orlando). Highlights include first‑in‑human results for the anti‑CD47 antibody HMPL‑A83, phase II data from the FRUSICA‑2 study of fruquintinib + sintilimab in second‑line renal cell carcinoma, and phase II results for surufatinib + camrelizumab + chemotherapy in first‑line metastatic pancreatic cancer. The company will also provide updates on investigator‑initiated studies and the final analysis of the phase III ESLIM‑01 sovleplenib study in chronic primary immune thrombocytopenia.
Insights
HUTCHMED will present multiple clinical data readouts at ESMO Asia (Dec 5‑7, 2025) and ASH (Dec 6‑9, 2025), including a Phase III final analysis.
Multiple late‑stage programs are moving to public disclosure through scheduled presentations: a first‑in‑human study of HMPL‑A83, phase II parts of the FRUSICA‑2 trial (fruquintinib + sintilimab) in second‑line renal cell carcinoma, a phase II portion of a randomized phase II/III study of surufatinib + camrelizumab + chemotherapy in first‑line metastatic pancreatic cancer, and the final analysis of the Phase III sovleplenib ESLIM‑01 trial in chronic primary immune thrombocytopenia. These disclosures mark formal clinical milestones and will provide the first detailed efficacy and safety datasets for several pipelines.
The market impact will hinge on the actual results—response rates, hazard ratios, safety signals and durability metrics—once the data are released. Investors should monitor the mini‑oral session for HMPL‑A83 on Dec 7, 2025, and the oral ASH session for sovleplenib on Dec 8, 2025.
Strategic and Market Implications
HUTCHMED’s portfolio reflects a diversified approach that blends novel immuno‑oncology agents (HMPL‑A83, surufatinib) with established vascular targeting strategies (fruquintinib, savolitinib). The anti‑CD47 antibody targets the “don’t eat me” signal, a mechanism that has garnered substantial interest after early successes with macrophage‑engaging therapies. Should HMPL‑A83 demonstrate a manageable safety profile and meaningful anti‑tumor activity, the company could position itself alongside market leaders such as Magrolimab and other CD47 blockers, potentially unlocking combination opportunities with checkpoint inhibitors.
The FRUSICA‑2 data will be critical for assessing the fruquintinib + sintilimab combo in renal cell carcinoma, a space dominated by VEGF‑TKI plus PD‑1/PD‑L1 regimens. A differentiated efficacy signal could expand fruquintinib’s addressable market beyond its current colorectal indication and strengthen HUTCHMED’s partnership with Eli Lilly.
Surufatinib’s multi‑kinase profile (VEGFR, FGFR, CSF‑1R) is designed to inhibit angiogenesis while modulating the tumor‑associated macrophage microenvironment. Positive phase II readouts in metastatic pancreatic cancer would enhance its positioning against established regimens such as FOLFIRINOX and gemcitabine‑nab‑paclitaxel, especially if the combination demonstrates synergistic activity with checkpoint inhibition.
The ESLIM‑01 final analysis could serve as a proof‑of‑concept for sovleplenib, an oral SYK inhibitor, in immune‑mediated thrombocytopenia. Success here may pave the way for broader applications in B‑cell malignancies and other autoimmune disorders, leveraging SYK’s central role in B‑cell receptor signaling.
Program Schedule
| Abstract title | Presenter / Lead author | Presentation details |
| ESMO Asia Congress 2025 – Sponsored Studies | ||
| A first‑in‑human dose escalation study of HMPL‑A83, an anti‑CD47 monoclonal antibody, in patients with advanced solid tumors | Ye Guo (Shanghai, China) | 162MO | Mini oral session: Developmental therapeutics and precision medicine Sunday, Dec 7, 2025, 11:40‑11:45 SGT, Hall 407 |
| Fruquintinib monotherapy as second‑line treatment in locally advanced or metastatic renal cell carcinoma: results from phase II part of FRUSICA‑2 | Shanshan Wang (Shanghai, China) | 540O | Proffered paper: Genitourinary tumours Friday, Dec 5, 2025, 14:55‑15:05 SGT, Hall 402 |
| Surufatinib + camrelizumab + nab‑paclitaxel + gemcitabine as first‑line treatment in metastatic pancreatic cancer: results from phase II part of a randomized open‑label study | Shukui Qin (Nanjing, China) | 375P | Poster: Gastrointestinal tumours, non‑colorectal |
| Osimertinib + savolitinib in EGFR‑mutated NSCLC with MET overexpression/amplification after progression on osimertinib: SAVANNAH Asian subset | Se‑Hoon Lee (Seoul, Korea) | 982P | Poster: Thoracic tumours, metastatic |
| Patient‑relevant outcomes from SACHI: Phase III trial of savolitinib + osimertinib vs chemotherapy in EGFR‑mutant, MET‑amplified NSCLC | Yongfeng Yu (Shanghai, China) | 984P | Poster: Thoracic tumours, metastatic |
| Analysis of MET amplification with FISH and NGS in the SACHI trial | Longhua Sun (Nanchang, China) | 988P | Poster: Thoracic tumours, metastatic |
| Progression patterns in EGFR‑mutant, MET‑amplified NSCLC treated with savolitinib + osimertinib | Haiyan Yang (Changsha, China) | 1002P | Poster: Thoracic tumours, metastatic |
| MET testing and treatment sequencing after progression on first‑line osimertinib in EGFR‑mutant NSCLC with acquired MET overexpression/amplification: final analysis of a global real‑world study | Julia Rotow (Boston, US) | 1005P | Poster: Thoracic tumours, metastatic |
| ESMO Asia Congress 2025 – Investigator‑initiated studies | ||
| Fruquintinib + TAS‑102 with or without SBRT as third‑ or later‑line treatment in metastatic colorectal cancer: prospective phase II results | Chen Zhang / Yi Wang (Ningbo, China) | 205P | Poster: Gastrointestinal tumours, colorectal |
| Efficacy and safety of fruquintinib + PD‑1 inhibitor + chidamide in MSS mCRC versus real‑world bevacizumab + PD‑1 + chidamide arm | Guanghai Dai / Miaomiao Gou (Beijing, China) | 245eP | Poster: Gastrointestinal tumours, colorectal |
| Efficacy and safety of fruquintinib + FOLFIRI as second‑line treatment in bevacizumab‑pretreated RAS‑mutated metastatic colorectal cancer | Zhenyang Liu / Xiaolin Yang (Changsha, China) | 250eP | Poster: Gastrointestinal tumours, colorectal |
| Real‑world observational study of fruquintinib + irinotecan + capecitabine as second‑line treatment in advanced colorectal cancer | Xiujuan Qu / Lin Xu (Shenyang, China) | 255eP | Poster: Gastrointestinal tumours, colorectal |
| Matching‑adjusted indirect comparison of surufatinib versus high‑dose octreotide LAR in advanced extrapancreatic neuroendocrine tumours | Jianming Xu (Beijing, China) | 214P | Poster: Gastrointestinal tumours, colorectal |
| Efficacy and safety of surufatinib + CAPTEM as conversion therapy in unresectable pancreatic neuroendocrine tumours: prospective open‑label data | Xubao Liu / Ziyao Wang (Chengdu, China) | 400P | Poster: Gastrointestinal tumours, non‑colorectal |
ASH Annual Meeting – Sponsored Study
| Abstract title | Presenter / Lead author | Presentation details |
| 2025 ASH Annual Meeting – Sponsored Studies | ||
| Phase III ESLIM‑01 study: Final analysis of efficacy and safety of long‑term sovleplenib treatment in adults with chronic primary immune thrombocytopenia | Renchi Yang (Tianjin, China) | 843 | Oral abstract session Monday, Dec 8, 2025, 15:15‑15:30 EST, Room OCCC‑W304EFGH |
Product Overviews
Fruquintinib is a selective oral inhibitor of VEGFR‑1, ‑2 and ‑3. Co‑developed and co‑commercialized in China by HUTCHMED and Eli Lilly under the brand ELUNATE®, it is licensed worldwide (outside mainland China, Hong Kong and Macau) to Takeda, which markets it as FRUZAQLA®.
HMPL‑A83 is an investigational IgG4‑type humanized anti‑CD47 monoclonal antibody that blocks the CD47‑SIRPα “don’t eat me” signal, potentially enhancing macrophage‑mediated tumor clearance. HUTCHMED retains worldwide rights.
Savolitinib is a potent, selective MET tyrosine‑kinase inhibitor being co‑developed by AstraZeneca and HUTCHMED and sold under the ORPATHYS® brand.
Surufatinib is an oral angio‑immuno kinase inhibitor targeting VEGFRs, FGFR, and CSF‑1R, marketed in China as SULANDA® with global rights held by HUTCHMED.
Sovleplenib is an oral, selective SYK inhibitor under investigation for B‑cell malignancies and autoimmune disorders, with worldwide rights retained by HUTCHMED.
Company Profile
HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is a commercial‑stage biopharmaceutical company focused on the discovery, development, and global commercialization of targeted therapies and immunotherapies for cancer and immune‑mediated diseases. Its pipeline includes three marketed products in China, one of which holds approvals in the United States, Europe and Japan.
FAQ
What clinical data will HUTCHMED present at ESMO Asia 2025?
The company will share first‑in‑human results for HMPL‑A83, phase II FRUSICA‑2 data for fruquintinib + sintilimab in second‑line renal cell carcinoma, and phase II data for surufatinib + camrelizumab + chemotherapy in metastatic pancreatic cancer.
When and where will HUTCHMED present at the 2025 ASH Annual Meeting?
The final analysis of the phase III ESLIM‑01 sovleplenib study will be presented on Dec 8, 2025, during the ASH meeting in Orlando.
Which study presents first‑in‑human data at ESMO Asia?
The dose‑escalation study of the anti‑CD47 antibody HMPL‑A83 is scheduled for a mini‑oral session on Dec 7, 2025.
What FRUSICA‑2 results will be reported?
Phase II results for fruquintinib monotherapy as second‑line treatment in locally advanced or metastatic renal cell carcinoma.
Does HUTCHMED present pancreatic cancer data at ESMO Asia?
Yes. Phase II data for surufatinib + camrelizumab with nab‑paclitaxel and gemcitabine as first‑line therapy for metastatic pancreatic cancer will be reported.
How can investors track presentation timings?
Investors can reference the official congress programs: ESMO Asia (Dec 5‑7, 2025) and ASH (Dec 6‑9, 2025) to locate session IDs and presentation slots listed by the company.
Original article, Author: Jam. If you wish to reprint this article, please indicate the source:https://aicnbc.com/13660.html
